Published in World J Biol Chem on April 26, 2012
Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One (2013) 1.03
Biological Insights into Therapeutic Protein Modifications throughout Trafficking and Their Biopharmaceutical Applications. Int J Cell Biol (2013) 0.85
Enzyme replacement with PEGylated cystathionine β-synthase ameliorates homocystinuria in murine model. J Clin Invest (2016) 0.81
Generation and preclinical characterization of an antibody specific for SEMA4D. MAbs (2015) 0.80
Challenges and opportunities in absorption, distribution, metabolism, and excretion studies of therapeutic biologics. AAPS J (2012) 0.80
Modeling pharmacokinetics/pharmacodynamics of abatacept and disease progression in collagen-induced arthritic rats: a population approach. J Pharmacokinet Pharmacodyn (2013) 0.80
Absorption, distribution, metabolism, and excretion (ADME) studies of biotherapeutics for autoimmune and inflammatory conditions. AAPS J (2012) 0.80
Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development. MAbs (2015) 0.78
Impact of SPR biosensor assay configuration on antibody: Neonatal Fc receptor binding data. MAbs (2016) 0.77
A Helix-Stabilizing Linker Improves Subcutaneous Bioavailability of a Helical Peptide Independent of Linker Lipophilicity. Bioconjug Chem (2016) 0.77
Site-specific functionalization of proteins and their applications to therapeutic antibodies. Comput Struct Biotechnol J (2014) 0.77
Bioactive protein fraction DLBS1033 containing lumbrokinase isolated from Lumbricus rubellus: ex vivo, in vivo, and pharmaceutic studies. Drug Des Devel Ther (2014) 0.77
Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura. EBioMedicine (2015) 0.76
An HIV gp120-CD4 Immunogen Does Not Elicit Autoimmune Antibody Responses in Cynomolgus Macaques. Clin Vaccine Immunol (2016) 0.76
Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice. Biopharm Drug Dispos (2016) 0.75
Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications. J Immunol Res (2016) 0.75
Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A. Toxins (Basel) (2016) 0.75
Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates. MAbs (2017) 0.75
Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol (2010) 4.21
Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther (2008) 4.17
The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem (2002) 4.11
The role of sialic acid in determining the survival of glycoproteins in the circulation. J Biol Chem (1971) 3.73
Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA (2011) 3.58
Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum (2007) 3.38
Multiple roles for the major histocompatibility complex class I- related receptor FcRn. Annu Rev Immunol (2000) 3.19
The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia (2003) 3.10
Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol (2005) 2.82
Developing the nation's biosimilars program. N Engl J Med (2011) 2.74
Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest (1999) 2.61
Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem (2006) 2.58
Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol (2007) 2.45
Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. Kidney Int (1979) 2.45
Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol (1989) 2.42
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther (2009) 2.36
Enhanced antibody half-life improves in vivo activity. Nat Biotechnol (2010) 2.33
Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol (2006) 2.32
Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today (2006) 2.21
Mass spectrometry based targeted protein quantification: methods and applications. J Proteome Res (2009) 2.20
Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev (2008) 2.16
"Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol (2007) 2.11
Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet (2010) 2.08
Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol (2002) 2.00
Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res (2010) 1.98
Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol (2009) 1.93
An engineered human IgG1 antibody with longer serum half-life. J Immunol (2006) 1.88
Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn (2007) 1.82
Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction. Curr Pharm Biotechnol (2002) 1.81
Fc receptors and their interactions with immunoglobulins. Annu Rev Cell Dev Biol (1996) 1.79
High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology (2011) 1.68
Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol (2009) 1.66
Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol (2010) 1.65
Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel (2010) 1.64
Physiological and pathological aspects of circulating immune complexes. Kidney Int (1989) 1.57
Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences. Drug Metab Dispos (2011) 1.54
Neonatal Fc receptor: from immunity to therapeutics. J Clin Immunol (2010) 1.50
Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog (2005) 1.49
Pharmacological significance of glycosylation in therapeutic proteins. Curr Opin Biotechnol (2009) 1.47
The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis (2011) 1.42
Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor. J Biol Chem (2006) 1.42
Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life. Mol Immunol (2005) 1.42
Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos (2010) 1.38
Monoclonal antibodies in cancer therapy: 25 years of progress. J Clin Oncol (2008) 1.38
Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy. BioDrugs (2010) 1.37
Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations. Drugs (2011) 1.36
PEG-modified biopharmaceuticals. Expert Opin Drug Deliv (2009) 1.34
A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res (2007) 1.32
Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem (2010) 1.32
Heterogeneity of recombinant antibodies: linking structure to function. Dev Biol (Basel) (2005) 1.31
Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates. Drug Metab Dispos (2006) 1.28
The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol (2010) 1.27
Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Clin Pharmacokinet (2011) 1.27
Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm Res (2006) 1.26
Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs (2010) 1.26
Pharmacokinetic aspects of biotechnology products. J Pharm Sci (2004) 1.25
Report of the National Heart, Lung, and Blood Institute working group on the translation of cardiovascular molecular imaging. Circulation (2011) 1.23
Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods (2009) 1.23
Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res (1990) 1.22
Mechanisms of immune-deposit formation and the mediation of immune renal injury. Clin Exp Nephrol (2005) 1.19
A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng (2005) 1.18
Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics. Expert Opin Drug Metab Toxicol (2009) 1.18
Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody. J Pharm Sci (2010) 1.15
Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther (2005) 1.13
Safety of biologics, lessons learnt from TGN1412. Curr Opin Biotechnol (2009) 1.12
Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol (2007) 1.12
Inhaled insulin--does it become reality? J Physiol Pharmacol (2008) 1.12
Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin J Am Soc Nephrol (2008) 1.11
Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers. Curr Opin Pharmacol (2005) 1.10
Antibody variable region glycosylation: position effects on antigen binding and carbohydrate structure. EMBO J (1991) 1.09
In vitro potency, pharmacokinetic profiles, and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupus. MAbs (2010) 1.09
The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies. Curr Opin Biotechnol (2009) 1.07
Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4. MAbs (2011) 1.06
Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. Pharm Res (2011) 1.04
The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points. Cancer Res (1999) 1.03
Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons. Pharm Res (2010) 1.01
Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice. Biologicals (2007) 1.01
Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis. J Pharmacokinet Pharmacodyn (2009) 1.01
Thrombotic complications of erythropoiesis-stimulating agents. Semin Thromb Hemost (2010) 1.00
Complex pharmacokinetics of a humanized antibody against human amyloid beta peptide, anti-abeta Ab2, in nonclinical species. Pharm Res (2011) 0.98
N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies. J Biol Chem (2008) 0.98
Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies. Curr Drug Metab (2009) 0.98
Subcutaneous administration of biotherapeutics: current experience in animal models. Curr Opin Mol Ther (2010) 0.98
Characterization of a complex glycoprotein whose variable metabolic clearance in humans is dependent on terminal N-acetylglucosamine content. Biologicals (2007) 0.97
Developmental and reproductive toxicology studies in nonhuman primates. Birth Defects Res B Dev Reprod Toxicol (2009) 0.95
Proteins in bile: how they get there and what they do. Am J Physiol (1984) 0.95
Biodistribution of [125I]-labeled therapeutic proteins: application in protein drug development beyond oncology. J Pharm Sci (2010) 0.94
Clinical ramifications of the MHC family Fc receptor FcRn. J Clin Immunol (2010) 0.94
Novel approaches to enhance pulmonary delivery of proteins and peptides. J Physiol Pharmacol (2007) 0.94
Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans. Curr Opin Mol Ther (2004) 0.94
Optimizing therapeutic antibody function: progress with Fc domain engineering. BioDrugs (2011) 0.93
Polysialic acids: potential in improving the stability and pharmacokinetics of proteins and other therapeutics. Cell Mol Life Sci (2000) 0.93
Erythropoietin-induced, antibody-mediated pure red cell aplasia. Eur J Clin Invest (2005) 0.92
Mechanism of transfer of immune complexes from red blood cell CR1 to monocytes. Clin Exp Immunol (1992) 0.92
The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model. Eur J Pharm Biopharm (2007) 0.92
Pharmacokinetics of IgG1 monoclonal antibodies produced in humanized Pichia pastoris with specific glycoforms: a comparative study with CHO produced materials. Biologicals (2011) 0.91
Correlation of pharmacodynamic activity, pharmacokinetics, and anti-product antibody responses to anti-IL-21R antibody therapeutics following IV administration to cynomolgus monkeys. J Transl Med (2010) 0.90
Bioanalysis of siRNA and oligonucleotide therapeutics in biological fluids and tissues. Bioanalysis (2009) 0.90
A draft sequence of the rice genome (Oryza sativa L. ssp. indica). Science (2002) 42.78
Family-based tests for associating haplotypes with general phenotype data: application to asthma genetics. Genet Epidemiol (2004) 5.57
RePS: a sequence assembler that masks exact repeats identified from the shotgun data. Genome Res (2002) 4.35
A multivariate family-based association test using generalized estimating equations: FBAT-GEE. Biostatistics (2003) 3.52
Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog (2009) 3.05
DAPK1 interaction with NMDA receptor NR2B subunits mediates brain damage in stroke. Cell (2010) 2.87
A common haplotype of the nicotine acetylcholine receptor alpha 4 subunit gene is associated with vulnerability to nicotine addiction in men. Am J Hum Genet (2004) 2.47
Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol (2008) 2.45
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol (2012) 2.43
Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. Am J Pathol (2002) 2.26
Connexins and cell signaling in development and disease. Annu Rev Cell Dev Biol (2004) 2.25
Extracellular superoxide dismutase deficiency exacerbates pressure overload-induced left ventricular hypertrophy and dysfunction. Hypertension (2007) 2.20
Upregulation of arginase by H2O2 impairs endothelium-dependent nitric oxide-mediated dilation of coronary arterioles. Arterioscler Thromb Vasc Biol (2006) 2.12
Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther (2012) 2.03
An MRI-based atlas and database of the developing mouse brain. Neuroimage (2010) 1.99
IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis. J Immunol (2007) 1.96
Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother (2004) 1.86
Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol (2004) 1.83
Synovial fibroblasts promote osteoclast formation by RANKL in a novel model of spontaneous erosive arthritis. Arthritis Rheum (2005) 1.79
miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat Cell Biol (2013) 1.79
Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure. Circ Res (2007) 1.73
Downregulation of adipose glutathione S-transferase A4 leads to increased protein carbonylation, oxidative stress, and mitochondrial dysfunction. Diabetes (2010) 1.70
The effects of light on bleaching and tooth sensitivity during in-office vital bleaching: a systematic review and meta-analysis. J Dent (2012) 1.67
Effects of age at menarche, reproductive years, and menopause on metabolic risk factors for cardiovascular diseases. Atherosclerosis (2007) 1.67
Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs (2011) 1.66
IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys. J Allergy Clin Immunol (2007) 1.63
Formation and differentiation of multiple mesenchymal lineages during lung development is regulated by beta-catenin signaling. PLoS One (2008) 1.63
Stent graft-induced new entry after endovascular repair for Stanford type B aortic dissection. J Vasc Surg (2010) 1.62
Connexin43 associated with an N-cadherin-containing multiprotein complex is required for gap junction formation in NIH3T3 cells. J Biol Chem (2005) 1.59
Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci (2002) 1.58
Anesthesia with nontracheal intubation in thoracic surgery. J Thorac Dis (2012) 1.56
Oxidative stress regulates left ventricular PDE5 expression in the failing heart. Circulation (2010) 1.54
AMP activated protein kinase-alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Hypertension (2008) 1.54
PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis. J Neuroimmunol (2006) 1.52
Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Ther (2009) 1.51
Kinase-inactive glycogen synthase kinase 3beta promotes Wnt signaling and mammary tumorigenesis. Cancer Res (2005) 1.50
Eya1 is required for the morphogenesis of mammalian thymus, parathyroid and thyroid. Development (2002) 1.49
Enhanced tumor retention of a radiohalogen label for site-specific modification of antibodies. J Med Chem (2013) 1.49
PGC-1 alpha regulates expression of myocardial mitochondrial antioxidants and myocardial oxidative stress after chronic systolic overload. Antioxid Redox Signal (2010) 1.48
Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys. Antimicrob Agents Chemother (2004) 1.48
Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci (2002) 1.44
Doubly hybrid density functional xDH-PBE0 from a parameter-free global hybrid model PBE0. J Chem Phys (2012) 1.44
A potential probe set of fluorescence in situ hybridization for detection of lung cancer in bronchial brushing specimens. J Cancer Res Clin Oncol (2012) 1.43
Activation of different Wnt/beta-catenin signaling components in mammary epithelium induces transdifferentiation and the formation of pilar tumors. Oncogene (2002) 1.43
A strategy for risk mitigation of antibodies with fast clearance. MAbs (2013) 1.42
A longitudinal assessment of coronary interventional program quality: a report from the American College of Cardiology-National Cardiovascular Data Registry. JACC Cardiovasc Interv (2009) 1.41
Long-term outcome of hybrid surgical approach of video-assisted minithoracotomy sleeve lobectomy for non-small-cell lung cancer. Surg Endosc (2011) 1.40
Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Bioconjug Chem (2011) 1.40
Long-term outcome and cost-effectiveness of complete versus assisted video-assisted thoracic surgery for non-small cell lung cancer. J Surg Oncol (2011) 1.40
Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos (2010) 1.38
Functional genomic screens identify CINP as a genome maintenance protein. Proc Natl Acad Sci U S A (2009) 1.38
Origins of phase contrast in the atomic force microscope in liquids. Proc Natl Acad Sci U S A (2009) 1.38
A new multimarker test for family-based association studies. Genet Epidemiol (2007) 1.34
Retrograde type A aortic dissection after endovascular stent graft placement for treatment of type B dissection. Circulation (2009) 1.33
Role of the urate transporter SLC2A9 gene in susceptibility to gout in New Zealand Māori, Pacific Island, and Caucasian case-control sample sets. Arthritis Rheum (2009) 1.32
Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem (2010) 1.32
Power estimation of multiple SNP association test of case-control study and application. Genet Epidemiol (2004) 1.31
Differential regulation of membrane guanylyl cyclases in congestive heart failure: natriuretic peptide receptor (NPR)-B, Not NPR-A, is the predominant natriuretic peptide receptor in the failing heart. Endocrinology (2007) 1.31
Cytosolic phospholipase A2 alpha-deficient mice are resistant to experimental autoimmune encephalomyelitis. J Exp Med (2005) 1.30
Variation in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with bone mineral density at different skeletal sites in men. Hum Genet (2005) 1.30
Amplification and overexpression of CTTN (EMS1) contribute to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and anoikis resistance. Cancer Res (2006) 1.29
Extracellular superoxide dismutase protects the heart against oxidative stress and hypertrophy after myocardial infarction. Free Radic Biol Med (2007) 1.29
Problems with the microbial production of butanol. J Ind Microbiol Biotechnol (2009) 1.28
Targeting Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases. J Biol Chem (2011) 1.28
Cyclin-dependent kinase 2 dependent phosphorylation of ATRIP regulates the G2-M checkpoint response to DNA damage. Cancer Res (2007) 1.27
EPAC null mutation impairs learning and social interactions via aberrant regulation of miR-124 and Zif268 translation. Neuron (2012) 1.27
Elevated expression of p63 protein in human esophageal squamous cell carcinomas. Int J Cancer (2002) 1.26
New alkali doped pillared carbon materials designed to achieve practical reversible hydrogen storage for transportation. Phys Rev Lett (2004) 1.25
Adenosine A3 receptor deficiency exerts unanticipated protective effects on the pressure-overloaded left ventricle. Circulation (2008) 1.24
Prevalence of metabolic syndrome and its relation to body composition in a Chinese rural population. Obesity (Silver Spring) (2006) 1.24
Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma. Int J Cancer (2009) 1.23
Mechanism for antibody catalysis of the oxidation of water by singlet dioxygen. Proc Natl Acad Sci U S A (2002) 1.23
A candidate gene association study on preterm delivery: application of high-throughput genotyping technology and advanced statistical methods. Hum Mol Genet (2004) 1.23
In situ growth of Co(0.85)Se and Ni(0.85)Se on conductive substrates as high-performance counter electrodes for dye-sensitized solar cells. J Am Chem Soc (2012) 1.22
Treatment of symptomatic isolated dissection of superior mesenteric artery. J Vasc Surg (2013) 1.22
Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J Clin Oncol (2005) 1.22
Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics. AAPS J (2012) 1.20
Amplification of PRKCI, located in 3q26, is associated with lymph node metastasis in esophageal squamous cell carcinoma. Genes Chromosomes Cancer (2008) 1.20
Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine. Arterioscler Thromb Vasc Biol (2011) 1.19
Collaborative development of 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick type C1 disease. Curr Top Med Chem (2014) 1.19
USP21 negatively regulates antiviral response by acting as a RIG-I deubiquitinase. J Exp Med (2014) 1.18
Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response. Clin Cancer Res (2012) 1.17
Spermatogenesis of mice lacking CK2alpha': failure of germ cell survival and characteristic modifications of the spermatid nucleus. Mol Reprod Dev (2003) 1.17
Revealing the molecular structure of single-molecule junctions in different conductance states by fishing-mode tip-enhanced Raman spectroscopy. Nat Commun (2011) 1.17
Dimethylarginine dimethylaminohydrolase and endothelial dysfunction in failing hearts. Am J Physiol Heart Circ Physiol (2005) 1.16
Age-related increase of tumor susceptibility is associated with myeloid-derived suppressor cell mediated suppression of T cell cytotoxicity in recombinant inbred BXD12 mice. Mech Ageing Dev (2007) 1.14
Feasibility of complete video-assisted thoracoscopic surgery following neoadjuvant therapy for locally advanced non-small cell lung cancer. J Thorac Dis (2013) 1.13
Renal hyporesponsiveness to atrial natriuretic peptide in congestive heart failure results from reduced atrial natriuretic peptide receptor concentrations. Am J Physiol Renal Physiol (2007) 1.13
miR-26a inhibits proliferation and motility in bladder cancer by targeting HMGA1. FEBS Lett (2013) 1.12
Visual saliency based on scale-space analysis in the frequency domain. IEEE Trans Pattern Anal Mach Intell (2013) 1.12
MicroRNA-124-3p inhibits cell migration and invasion in bladder cancer cells by targeting ROCK1. J Transl Med (2013) 1.11
Optimization of fatty alcohol biosynthesis pathway for selectively enhanced production of C12/14 and C16/18 fatty alcohols in engineered Escherichia coli. Microb Cell Fact (2012) 1.11
Three isoforms of annexin I are preferentially expressed in normal esophageal epithelia but down-regulated in esophageal squamous cell carcinomas. Oncogene (2002) 1.11
Parallel phosphatidylinositol-3 kinase and p42/44 mitogen-activated protein kinase signaling pathways subserve the mitogenic and antiapoptotic actions of insulin-like growth factor I in osteoblastic cells. Endocrinology (2003) 1.10
Vascular endothelial-specific dimethylarginine dimethylaminohydrolase-1-deficient mice reveal that vascular endothelium plays an important role in removing asymmetric dimethylarginine. Circulation (2009) 1.10
Recurrent immature teratoma of the ovary: a case report of radical secondary cytoreduction with replacement of the aortic bifurcation. Gynecol Oncol (2004) 1.10
CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis. J Clin Invest (2003) 1.10